Literature DB >> 11146554

The HPV16 E5 oncogene inhibits endocytic trafficking.

P Thomsen1, B van Deurs, B Norrild, L Kayser.   

Abstract

The small hydrophobic E5 protein of Human Papillomavirus type 16 (HPV16) binds to the 16-kDa subunit of the V-H+-ATPase. This binding has been suggested to interfere with acidification of late endocytic structures. We here used video microscopy, ratio imaging and confocal microscopy of living C127 fibroblasts to study the effects of E5. Various endocytic markers including the pH-sensitive probe DM-NERF coupled to dextran, TransFluoSpheres and TRITC-concanavalin A, were applied. In E5-transfected cells, none of these markers colocalized with the membrane permeable probe LysoTracker Red, which accumulates in acidic, late endocytic structures, or with a green fluorescent version of the small GTPase Rab7 labeling late endocytic structures. Importantly, however, late endocytic structures accumulating LysoTracker were still present in the E5-transfected cells. It is therefore concluded that HPV16 E5 perturbs trafficking from early to late endocytic structures rather than acidification.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11146554     DOI: 10.1038/sj.onc.1204010

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification.

Authors:  Frank A Suprynowicz; Ewa Krawczyk; Jess D Hebert; Sawali R Sudarshan; Vera Simic; Christopher M Kamonjoh; Richard Schlegel
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms.

Authors:  Kirsten Kabsch; Angel Alonso
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 4.  Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value.

Authors:  Niladri Ganguly
Journal:  Cell Oncol (Dordr)       Date:  2012-01-20       Impact factor: 6.730

5.  Quantitative measurement of human papillomavirus type 16 e5 oncoprotein levels in epithelial cell lines by mass spectrometry.

Authors:  Ziad Sahab; Sawali R Sudarshan; Xuefeng Liu; YiYu Zhang; Alexander Kirilyuk; Christopher M Kamonjoh; Vera Simic; Yuhai Dai; Stephen W Byers; John Doorbar; Frank A Suprynowicz; Richard Schlegel
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

6.  E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis.

Authors:  Benyue Zhang; Dan F Spandau; Ann Roman
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.

Authors:  Abdul A Waheed; Maya Swiderski; Ali Khan; Ariana Gitzen; Ahlam Majadly; Eric O Freed
Journal:  J Biol Chem       Date:  2020-04-14       Impact factor: 5.157

8.  Karyopherin beta3: a new cellular target for the HPV-16 E5 oncoprotein.

Authors:  Ewa Krawczyk; John A Hanover; Richard Schlegel; Frank A Suprynowicz
Journal:  Biochem Biophys Res Commun       Date:  2008-05-01       Impact factor: 3.575

9.  Characterization of the plasma membrane localization and orientation of HPV16 E5 for cell-cell fusion.

Authors:  Lulin Hu; Brian P Ceresa
Journal:  Virology       Date:  2009-08-26       Impact factor: 3.616

10.  Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.

Authors:  Yi-Fang Chen; Chih-Wei Lin; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.